Crossmark

Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository

Crossref DOI link: https://doi.org/10.1186/s42358-021-00222-3

Published Online: 2021-10-28

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

de Azevedo Lopes, Erivelton

Balbi, Gustavo Guimarães Moreira

Tektonidou, Maria G.

Pengo, Vittorio

Sciascia, Savino

Ugarte, Amaia

Belmont, H. Michael

Gerosa, Maria

Fortin, Paul R.

Lopez-Pedrera, Chary

Ji, Lanlan

Cohen, Hannah

de Jesús, Guilherme Ramires

Branch, D. Ware

Nalli, Cecilia

Petri, Michelle

Rodriguez, Esther

Kello, Nina

Ríos-Garcés, Roberto

Knight, Jason S.

Atsumi, Tatsuya

Willis, Rohan

Bertolaccini, Maria Laura

Erkan, Doruk

Andrade, Danieli http://orcid.org/0000-0002-0381-1808
,
License Information

Text and Data Mining valid from 2021-10-28

Version of Record valid from 2021-10-28
More Information

Article History

Received: 9 July 2021

Accepted: 11 October 2021

First Online: 28 October 2021

Declarations

:

: This study was performed using data from the APS ACTION Registry. During recruitment, each center received ethical approval of your local committee. The study protocol was submitted for approval by the APS ACTION Committee. All patients included in this study signed a written informed consent during APS ACTION Registry recruitment.

: Not applicable.

: The authors declare that they have no competing interests regarding this paper.

Document is current

Any future updates will be listed below